340 related articles for article (PubMed ID: 31805992)
21. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors.
Terslev L; Ostergaard M; Georgiadis S; Brahe CH; Ellegaard K; Dohn UM; Fana V; Møller T; Juul L; Huynh TK; Krabbe S; Ornbjerg LM; Glinatsi D; Røgind H; Hansen A; Nørregaard J; Jacobsen S; Jensen DV; Manilo N; Asmussen K; Boesen M; Rastiemadabadi Z; Morsel-Carlsen L; Møller JM; Krogh NS; Hetland ML
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549857
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study.
Yoshida S; Kotani T; Kimura Y; Matsumura Y; Yoshikawa A; Tokai N; Ozaki T; Nagai K; Takeuchi T; Makino S; Arawaka S
Int J Rheum Dis; 2019 Jan; 22(1):81-89. PubMed ID: 30168272
[TBL] [Abstract][Full Text] [Related]
23. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial.
Tascilar K; Hagen M; Kleyer A; Simon D; Reiser M; Hueber AJ; Manger B; Englbrecht M; Finzel S; Tony HP; Schuch F; Kleinert S; Wendler J; Ronneberger M; Figueiredo CP; Cobra JF; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Kruger K; Henes J; Schett G; Rech J
Lancet Rheumatol; 2021 Nov; 3(11):e767-e777. PubMed ID: 38297524
[TBL] [Abstract][Full Text] [Related]
24. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A
Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417
[TBL] [Abstract][Full Text] [Related]
25. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.
van Mulligen E; de Jong PHP; Kuijper TM; van der Ven M; Appels C; Bijkerk C; Harbers JB; de Man Y; Molenaar THE; Tchetverikov I; Goekoop-Ruiterman YPM; van Zeben J; Hazes JMW; Weel AEAM; Luime JJ
Ann Rheum Dis; 2019 Jun; 78(6):746-753. PubMed ID: 30954969
[TBL] [Abstract][Full Text] [Related]
26. DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.
Verstappen M; van Mulligen E; de Jong PHP; van der Helm-Van Mil AHM
RMD Open; 2020 May; 6(1):. PubMed ID: 32393523
[TBL] [Abstract][Full Text] [Related]
27. MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis.
Barendregt AM; Veldkamp SR; Hissink Muller PCE; van de Geer A; Aarts C; van Gulik EC; Schilham MW; Kessel C; Keizer MP; Hemke R; Nassar-Sheikh Rashid A; Dolman KM; Schonenberg-Meinema D; Ten Cate R; van den Berg JM; Maas M; Kuijpers TW
Rheumatology (Oxford); 2020 Sep; 59(9):2392-2401. PubMed ID: 31904851
[TBL] [Abstract][Full Text] [Related]
28. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
29. Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis.
Nordal HH; Fagerhol MK; Halse AK; Hammer HB
Scand J Clin Lab Invest; 2018; 78(1-2):102-108. PubMed ID: 29278951
[TBL] [Abstract][Full Text] [Related]
30. Validation and predictive capacity of a Dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial.
Doumen M; Bertrand D; Pazmino S; De Cock D; Stouten V; Joly J; de Wergifosse I; Moeyersoons A; Westhovens R; Verschueren P
Clin Rheumatol; 2023 Jan; 42(1):39-45. PubMed ID: 35943667
[TBL] [Abstract][Full Text] [Related]
31. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.
van Mulligen E; Weel AE; Hazes JM; van der Helm-van Mil A; de Jong PHP
Ann Rheum Dis; 2020 Sep; 79(9):1174-1181. PubMed ID: 32482645
[TBL] [Abstract][Full Text] [Related]
32. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.
Hurnakova J; Hulejova H; Zavada J; Komarc M; Hanova P; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
PLoS One; 2016; 11(11):e0165498. PubMed ID: 27832086
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.
Tweehuysen L; den Broeder N; van Herwaarden N; Joosten LAB; van Lent PL; Vogl T; van den Hoogen FHJ; Thurlings RM; den Broeder AA
RMD Open; 2018; 4(1):e000654. PubMed ID: 29657832
[TBL] [Abstract][Full Text] [Related]
34. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
Hurnakova J; Zavada J; Hanova P; Hulejova H; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Komarc M; Vencovsky J; Pavelka K; Senolt L
Arthritis Res Ther; 2015 Sep; 17(1):252. PubMed ID: 26373925
[TBL] [Abstract][Full Text] [Related]
35. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R
Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859
[TBL] [Abstract][Full Text] [Related]
36. Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.
Lamers-Karnebeek FBG; Jacobs JWG; Radstake TRDJ; van Riel PLCM; Jansen TL
Rheumatology (Oxford); 2019 Mar; 58(3):427-431. PubMed ID: 30383251
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
Emery P; Burmester GR; Naredo E; Sinigaglia L; Lagunes I; Koenigsbauer F; Conaghan PG
Ann Rheum Dis; 2020 Aug; 79(8):1023-1030. PubMed ID: 32404343
[TBL] [Abstract][Full Text] [Related]
38. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
Messelink MA; van der Leeuw MS; den Broeder AA; Tekstra J; van der Goes MC; Heijstek MW; Lafeber F; Welsing PMJ
Trials; 2022 Jun; 23(1):494. PubMed ID: 35710576
[TBL] [Abstract][Full Text] [Related]
39. IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritis.
Sokolova MV; Hagen M; Bang H; Schett G; Rech J; Steffen U;
Rheumatology (Oxford); 2022 May; 61(5):2124-2131. PubMed ID: 34508547
[TBL] [Abstract][Full Text] [Related]
40. Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs.
Vodencarevic A; Tascilar K; Hartmann F; Reiser M; Hueber AJ; Haschka J; Bayat S; Meinderink T; Knitza J; Mendez L; Hagen M; Krönke G; Rech J; Manger B; Kleyer A; Zimmermann-Rittereiser M; Schett G; Simon D;
Arthritis Res Ther; 2021 Feb; 23(1):67. PubMed ID: 33640008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
